A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

Sponsor
Genentech, Inc.
Study ID
NCT00109239
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This Phase III, multicenter, randomized, active-controlled, open-label trial is designed to evaluate the efficacy, safety, and pharmacokinetics of rhuMAb VEGF when combined with capecitabine compared with capecitabine alone in subjects with previously treated metastatic breast cancer.

Key Dates

First listed
Apr 26, 2005
Start date
Nov 30, 2000
Status verified
Jun 2013
Completion
Sep 30, 2002

Study Design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Related Studies